Marko Bagaric is responsible for the Company’s general business development and investor relations. At the age of 22 he founded his own business and started to gather insights in the real estate and financial sectors.
He brings substantial knowhow in private equity and corporate investment. Since the establishment of his own company, Minerva Partners AG in 2011, he has repeatedly demonstrated his ability to support entrepreneurs with financing and management needs.
Today, at Berlin Cures, he leads the development of BC 007 and the respective clinical trials.Mr. Bagaric also acts as Chief Executive Officer of Berlin Heals Holding AG, a company which is developing an electroceutical device to treat heart failure by readjusting the disturbed myocardial electrical gradient.